Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO)
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that eventually leads to end-stage liver failure and death unless liver transplantation (LT) is performed. Ursodeoxycholic acid (UDCA) administered orally at the daily dose of 13-15 mg/kg is currently the only drug approved for the treatment of PBC. UDCA consistently improves biochemical liver tests, prolongs survival without LT, and delays histological progression as well as the occurrence of portal hypertension. However, a significant proportion (40%) of patients treated with UDCA shows an incomplete biochemical response and remains at high risk of death or LT. The development of new treatments in combination with UDCA is therefore needed. Several candidates exist among which is Bezafibrate. Bezafibrate belongs to the fibrates' pharmacological class, which has been developed 4 decades ago for the treatment of mixed hyperlipidaemia. Bezafibrate is cheap, widely available and well tolerated. There is now a substantial body of circumstantial evidence supporting that fibrates, and Bezafibrate in particular, are well tolerated and can improve biochemical liver tests in patients with PBC with incomplete response to UDCA. However, despite several positive successful pilot studies, there are still no phase 3 randomized placebo-controlled trials of fibrates for the treatment of PBC. The purpose of this protocol is therefore to conduct such a trial in a selected population of patients with PBC based on an incomplete biochemical response after 6 months of UDCA therapy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.|
- Percentage of patients with complete biochemical response. [ Time Frame: 24 months ] [ Designated as safety issue: No ]The normalisation of hepatic biochemical tests (aminotransferases (AST, ALT), Alkaline Phosphatase, blood Albumin, blood bilirubin and prothrombin index).
- Percentage of patients having biological or clinical adverse reaction. [ Time Frame: 30 months ] [ Designated as safety issue: No ]Increase of ALT, AST or CPK > 5N
- Percentage of patients having complete biochemical response. [ Time Frame: 12 months ] [ Designated as safety issue: No ]Percentage of patients having complete biochemical response at Month 12.
- Evolution of the pruritus. [ Time Frame: 24 months ] [ Designated as safety issue: No ]Pruritus is measured via visual analogical scale every 3 months from month 0 to month 24
- Assessment of the fatigue and the quality of life. [ Time Frame: 24 months ] [ Designated as safety issue: No ]Measured via French questionnaire version of NHP (Nottingham Health Profile) every 12 months from month 0 to month 24
- Evolution of liver fibrosis surrogate markers. [ Time Frame: 24 months ] [ Designated as safety issue: No ]assessment of hyaluronic acid serum concentration and hepatic transient elastography (Fibroscan®)
- Evolution of the portal hypertension markers. [ Time Frame: NC ] [ Designated as safety issue: No ]Occurrence of ascites, decrease in the platelet count below 150000/mm3 or of more than 30% of its initial value, evolution of the ultrasound data of the splanchnic circulation, occurrence or size progression of oesophageal varices (endoscopy)
- Histological evolution: Histopathological examination of biological sample before enrolment and at the end of the study. [ Time Frame: 30 months ] [ Designated as safety issue: No ]Quantification of the fibrosis and the inflammatory and destructive injuries.
- Evolution of the biological markers of the hepatic function or being in the usual prognostic scores (Mayo, Child, MELD). [ Time Frame: NC ] [ Designated as safety issue: No ]Blood albumin, prothrombin time, INR, blood bilirubin, creatinine blood level.
- Survival without transplantation and hepatic impairment. [ Time Frame: NC ] [ Designated as safety issue: No ]Occurrence of ascites, a digestive variceal bleeding, a hepatic encephalopathy, or a doubling of the total blood bilirubin exceeding the threshold of 50 µmols/L (3 mg/dl).
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||October 2015|
|Estimated Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
Placebo Comparator: Placebo
1 tablet/ day
This is a multi-center, randomized (treatment will be assigned by chance), placebo-controlled (an inactive substance will be compared with the test drug to see whether the drug has a real effect), parallel-group (two or more groups of patients will receive different treatments) study that will assess the efficacy and safety of bezafibrate in patients with primary biliary cirrhosis (PBC) who had an inadequate biochemical response to ursodeoxycholic acid, as defined by the Paris II criteria. Bezafibrate 400 mg or placebo will be daily administered in combination with ursodeoxycholic acid (UDCA) 13-15 mg/kg/d for 24 months. Patient safety will be monitored. Primary end-point will be the percentage of patients with a complete normalization of the following biochemical tests: alkaline phosphatase, aminotransferases, total bilirubin, serum albumin, and prothrombin index. Secondary endpoints will include the percentage of drug-related adverse events, survival rates without liver transplantation or liver decompensation, time course of non-invasive liver fibrosis measurements (Fibroscan, serum hyaluronic acid), time course of liver histological parameters (fibrosis stage, necro-inflammatory grade, ductopenia) assessed on percutaneous biopsy specimens, time course of endoscopic, ultrasound, and biochemical features of portal hypertension, time course of pruritus and of quality of life using validated scales.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01654731
|Contact: Christophe Corpechot, Doctor||+ 33 (0) 1 49 28 28 firstname.lastname@example.org|
|Hepatology department - Hopital Saint Antoine||Recruiting|
|Paris, France, 75012|
|Contact: Christophe Corpechot, Doctor + 33 (0) 1 49 28 28 36 email@example.com|
|Principal Investigator:||Christophe Corpechot, Doctor||Assistance Publique|